The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy
- 1 May 2002
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 12 (3) , 265-276
- https://doi.org/10.1046/j.1525-1438.2002.01121.x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Biomarker Conservation in Primary and Metastatic Epithelial Ovarian CancerGynecologic Oncology, 2000
- Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fractionBritish Journal of Cancer, 2000
- Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian CancersThe American Journal of Pathology, 2000
- Prognostic factors in early-onset epithelial ovarian cancer: a population-based studyPublished by Wolters Kluwer Health ,2000
- Transforming growth factor-? differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1Cancer, 1999
- The clinical predictivity of biomarkers of stage III‐IV epithelial ovarian cancer in a prospective randomized treatment protocolCancer, 1998
- Expression and prognostic significance of Bcl-2 in ovarian tumoursBritish Journal of Cancer, 1995
- Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significanceBritish Journal of Cancer, 1994
- p53 gene mutations and protein accumulation in human ovarian cancer.Proceedings of the National Academy of Sciences, 1993
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981